Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors
G Giaccone, Y Wang - Cancer treatment reviews, 2011 - Elsevier
The first-generation epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and
gefitinib have been incorporated into treatment paradigms for patients with advanced non …
gefitinib have been incorporated into treatment paradigms for patients with advanced non …
EGFR tyrosine kinase inhibitors: difference in efficacy and resistance
KW Robinson, AB Sandler - Current oncology reports, 2013 - Springer
Lung cancer will be diagnosed in 230,000 patients in the US in 2013. Adenocarcinoma will
be the most common histology, and 10% of lung cancers will be diagnosed in never or …
be the most common histology, and 10% of lung cancers will be diagnosed in never or …
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
PS Hammerman, PA Jänne, BE Johnson - Clinical cancer research, 2009 - AACR
Gefitinib and erlotinib are ATP competitive inhibitors of the epidermal growth factor receptor
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …
Epidermal growth factor receptor–mutant lung cancer: new drugs, new resistance mechanisms, and future treatment options
Z Piotrowska, LV Sequist - The Cancer Journal, 2015 - journals.lww.com
Epidermal growth factor receptor (EGFR) mutations define a subset of non–small cell lung
cancers that are sensitive to EGFR-targeted tyrosine kinase inhibitors (TKIs). Treatment with …
cancers that are sensitive to EGFR-targeted tyrosine kinase inhibitors (TKIs). Treatment with …
[HTML][HTML] Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
GJ Riely - Journal of Thoracic Oncology, 2008 - Elsevier
Approximately 10 to 15% of patients with non-small cell lung cancer have tumors that
depend on activation of the epidermal growth factor receptor (EGFR), as evidenced by …
depend on activation of the epidermal growth factor receptor (EGFR), as evidenced by …
Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and
erlotinib have provided substantial benefits to patients with advanced non–small cell lung …
erlotinib have provided substantial benefits to patients with advanced non–small cell lung …
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor …
KSH Nguyen, S Kobayashi, DB Costa - Clinical lung cancer, 2009 - Elsevier
Abstract Most advanced Non–Small-cell lung cancers (NSCLCs) with activating epidermal
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
JA Engelman, PA Jänne - Clinical Cancer Research, 2008 - AACR
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are
effective therapies for non–small cell lung cancer patients whose tumors harbor somatic …
effective therapies for non–small cell lung cancer patients whose tumors harbor somatic …
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
KSH Nguyen, JW Neal - Biologics: Targets and Therapy, 2012 - Taylor & Francis
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially
established as second-or third-line treatment of advanced non-small-cell lung cancer …
established as second-or third-line treatment of advanced non-small-cell lung cancer …
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
L Kujtan, J Subramanian - Expert Review of Anticancer Therapy, 2019 - Taylor & Francis
Introduction: Epidermal growth factor receptor (EGFR) mutations are well-described drivers
of non-small cell lung cancer (NSCLC) and EGFR tyrosine kinase inhibitors (TKIs) have …
of non-small cell lung cancer (NSCLC) and EGFR tyrosine kinase inhibitors (TKIs) have …